Ipamorelin cjc 1295

The most striking feature of combining ipamorelin with CJC-1295 is not that the pairing amplifies growth hormone release — it's that the two compounds attack the problem from opposite ends of the regulatory axis, creating a sustained pulse pattern that neither achieves alone. One extends the signal, the other amplifies it, and the result in animal models is a GH secretion curve that looks more like endogenous overnight release than the sharp, short spikes typical of most synthetic secretagogues.

Two Pentapeptides with Different Jobs in the GH Release Cascade

Ipamorelin is a synthetic five-amino-acid peptide (pentapeptide) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of 711.85 Da. It belongs to the growth hormone secretagogue class — compounds that trigger the pituitary gland to release its own growth hormone rather than supplying exogenous hormone. Developed in the late 1990s by Novo Nordisk, ipamorelin emerged from structure-activity research aimed at improving selectivity over earlier peptides like GHRP-6 and hexarelin, which also raised cortisol and prolactin.

CJC-1295, more accurately called Mod GRF (1-29) in its non-DAC form, is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) variant contains an additional lysine side-chain modification that binds albumin, extending half-life from minutes to approximately one week. Both forms preserve the GHRH receptor-binding sequence but resist enzymatic degradation far better than native GHRH, which dipeptidyl peptidase-IV (DPP-IV) cleaves within minutes.

The pairing strategy is straightforward: GHRH analogs like CJC-1295 tell the pituitary to release growth hormone, while ghrelin mimetics like ipamorelin amplify that signal. Stacking the two in rodent models produces greater GH release than either alone.

How the Two Compounds Hit Different Receptors in the Same Cells

Ipamorelin binds selectively to the growth hormone secretagogue receptor 1a (GHS-R1a), a Gq-coupled receptor concentrated in somatotroph cells of the anterior pituitary and the arcuate nucleus of the hypothalamus. GHS-R1a is the endogenous receptor for ghrelin, the gut-derived hunger peptide, but ipamorelin activates it independently. Receptor binding triggers intracellular calcium mobilization through phospholipase C and inositol trisphosphate pathways, which depolarizes somatotrophs and prompts vesicular release of growth hormone. Critically, ipamorelin does not activate cortisol or prolactin secretion at doses that produce robust GH pulses in animal studies — a key difference from earlier secretagogues like GHRP-2 and hexarelin.

CJC-1295 binds the GHRH receptor (GHRHR), a Gs-coupled receptor on the same somatotroph cells. GHRHR activation raises cyclic AMP (cAMP) through adenylyl cyclase, opening voltage-gated calcium channels and promoting transcription of the GH gene itself. GHRH signaling is tonic — it sets the baseline readiness of somatotrophs to release hormone when other signals arrive. Ipamorelin provides that additional signal. The two pathways converge on calcium influx and vesicular exocytosis but use separate upstream cascades.

The synergy appears mechanistic rather than additive. In porcine pituitary cell cultures, co-treatment with a GHRH analog and a ghrelin mimetic produced GH release approximately 1.5 to 2 times greater than the sum of the individual responses, suggesting true potentiation rather than simple addition. The most widely cited hypothesis is that GHRH increases the pool of GH-containing vesicles ready for release, while ghrelin receptor agonists trigger the release event itself. This makes the combination particularly relevant for research applications where pulsatile GH secretion patterns are studied.

What Rodent and Porcine Models Show About the Stack

The bulk of published data on ipamorelin and CJC-1295 combinations comes from studies using rodent or porcine somatotroph cells, not intact animals. In one frequently referenced porcine pituitary culture study, co-administration of a GHRH analog and a ghrelin mimetic (the class to which ipamorelin belongs) produced peak GH release 1.8-fold higher than GHRH alone and sustained the pulse for approximately 3 hours rather than the typical 60-90 minutes. This extended secretion window reflects the extended half-life of modified GHRH analogs, which resist DPP-IV cleavage.

In Sprague-Dawley rats, subcutaneous administration of ipamorelin at 300 μg/kg produced a GH pulse peaking at approximately 45 minutes post-injection. When co-administered with a short-acting GHRH analog at 100 μg/kg, the peak amplitude increased by roughly 60%, and plasma IGF-1 measured 24 hours later was approximately 40% higher than ipamorelin alone. The effect was dose-dependent and lost at ipamorelin doses below 100 μg/kg or GHRH doses below 30 μg/kg in that specific model.

Human data on the ipamorelin-CJC-1295 combination are sparse and mostly unpublished. A single Phase I safety study of ipamorelin monotherapy (not combined with CJC-1295) in healthy adult men reported transient increases in serum GH and IGF-1 at doses of 0.06 to 0.5 mg/kg, with no cortisol or prolactin elevation. No peer-reviewed Phase II trials of the combination in humans have been published as of 2026. Clinical use relies on extrapolation from animal models and single-agent human data.

The absence of controlled human efficacy data on the stack is not trivial. Rodent GH physiology differs from human in pulsatility, somatostatin tone, and IGF-1 feedback sensitivity. Whether the synergy observed in porcine pituitary cells translates to clinically meaningful outcomes in humans — and at what doses — remains uncharacterized in published literature. For research purposes only, this combination is studied in preclinical models where GH dynamics, body composition, and metabolic endpoints are measured.

Dosing, Half-Life, and Practical Parameters from Published Literature

In rodent studies, effective ipamorelin doses range from 100 to 500 μg/kg subcutaneously, typically administered once or twice daily. CJC-1295 without DAC (Mod GRF 1-29) is dosed at 30 to 100 μg/kg, with similar frequency. The DAC variant, which binds albumin and extends half-life to approximately 6-8 days in animal models, is dosed weekly at 50 to 200 μg/kg in research protocols. Stacking protocols in rodent literature typically use ipamorelin at 200-300 μg/kg with CJC-1295 no-DAC at 100 μg/kg, both given subcutaneously before a feeding or activity cycle to align with natural GH pulsatility.

Ipamorelin's plasma half-life in humans is approximately 2 hours based on unpublished pharmacokinetic data from the Phase I trial. CJC-1295 without DAC has a half-life of roughly 30 minutes, while the DAC form persists for days due to albumin binding. This half-life mismatch is why most stacking protocols use the non-DAC variant — the goal is to synchronize pulses, not create persistent elevation. Chronic elevation of GH or IGF-1 raises concerns about insulin resistance and tissue overgrowth in long-term animal studies.

Both peptides are typically reconstituted in bacteriostatic water and stored at 2-8°C. Once reconstituted, ipamorelin is stable for approximately 2 weeks under refrigeration; CJC-1295 degrades more rapidly, with an estimated stability window of 7-10 days. Freeze-thaw cycles degrade both peptides. Co-administration in the same syringe has not been studied for stability but is common in research practice.

One notable interaction: somatostatin tone suppresses the efficacy of both compounds. In rodent models where exogenous somatostatin was administered, ipamorelin and CJC-1295 showed blunted GH release. This suggests that conditions of high endogenous somatostatin (stress, hyperglycemia, high free fatty acids) may reduce the stack's effectiveness. Conversely, fasting or exercise, which lower somatostatin tone, enhance GH pulse amplitude in animal studies.

FAQ

Q: Why is ipamorelin considered more selective than older GH secretagogues?

Ipamorelin binds GHS-R1a without significantly activating cortisol or prolactin release at GH-effective doses in animal models. Earlier compounds like GHRP-6 and hexarelin showed dose-dependent cortisol and prolactin elevations, which limited their therapeutic window. This selectivity profile was established in rodent and porcine studies but has not been fully validated in long-term human trials.

Q: Does the combination work better with CJC-1295 DAC or the non-DAC form?

Most preclinical stacking protocols use the non-DAC form (Mod GRF 1-29) because its shorter half-life allows pulsatile dosing aligned with circadian GH rhythms. The DAC variant creates sustained elevation rather than pulses, which may reduce receptor sensitivity over time. Rodent studies suggest pulsatile GH release better preserves downstream signaling and minimizes feedback suppression compared to tonic elevation.

Q: What does the combination not do that is sometimes claimed?

It does not directly burn fat, build muscle, or extend lifespan. It raises GH and secondarily IGF-1, which influence those processes through downstream pathways involving lipolysis, protein synthesis, and glucose metabolism. The magnitude of those effects in humans is not quantified in controlled trials. Claims of dramatic body recomposition from short-term use are not supported by published human data.

Q: How long does the GH pulse last after co-administration?

In porcine cell culture, the pulse duration extends to approximately 3 hours with the combination, compared to 60-90 minutes for GHRH analogs alone. In Sprague-Dawley rats, plasma GH remains elevated for 2-3 hours post-injection. Human pharmacodynamics have not been characterized in peer-reviewed studies.

Q: Can you use the combination continuously or does tolerance develop?

Rodent studies using daily dosing for 4-6 weeks show preserved GH pulse amplitude with no evidence of tachyphylaxis. However, continuous use of the DAC variant in one unpublished canine study suggested receptor downregulation after 8 weeks. Pulsatile protocols using the non-DAC form appear to maintain efficacy longer, but human data on chronic use are absent.

---

This information is intended for educational and research purposes. Ipamorelin and CJC-1295 are investigational peptides not approved for human therapeutic use by regulatory agencies. Researchers and clinicians should consult current medical literature and regulatory guidelines before any experimental application.